RxDoctor Payments Data

Suresh Prasad, MD

Internal Medicine · Odessa, TXNPI 1053419572

Payments from drug & device makers

$89,814in general payments, 2019–2025

Across 151 payments — averaging $594.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$67K
  • Lilly USA, LLC$22K
  • Astellas Pharma US Inc$273
  • Harmony Biosciences LLC$177
  • AstraZeneca$73
  • GSK$71
  • plus $303 from 12 others

What the payments were for

  • Speaking & faculty fees$81,70291%
  • Travel & lodging$4,8255%
  • Food & beverage$2,9673%
  • Education$3200%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$89,814 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$268,167
Medicare patients
463
Services billed
4,025

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide137$205,633
MounjaroTirzepatide92$118,735
EliquisApixaban50$56,263
Tresiba Flextouch U-200Insulin Degludec64$48,916
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$27,630
JardianceEmpagliflozin30$27,211
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog28$26,613
JanuviaSitagliptin Phosphate17$26,392
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog16$16,504
FarxigaDapagliflozin Propanediol16$16,318
Fiasp FlextouchInsulin Aspart (Niacinamide)14$14,266
MyrbetriqMirabegron15$13,476
TradjentaLinagliptin11$8,364
Humalog Kwikpen U-100Insulin Lispro19$7,385
SymbicortBudesonide/Formoterol Fumarate16$4,253

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$67,315$205,633137 claims
Lilly USA, LLCMounjaro$21,603$118,73592 claims
PfizerEliquis$16$56,26350 claims
GSKTrelegy Ellipta$71$27,63019 claims
AstraZenecaFarxiga, Symbicort$73$20,57132 claims
Astellas Pharma US IncMyrbetriq$273$13,47615 claims
AbbVieSynthroid$18$92429 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Odessa

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →